Lercapress

Enalapril maleate and lercanidipine hydrochloride, the active ingredients in Lercapress, are an ACE inhibitor and a calcium‑channel blocker presented as an oral tablet for systemic use. They work together to lower blood pressure in adults with hypertension. GNH USA supplies Lercapress as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercapress is an antihypertensive combination that acts on the renin‑angiotensin system and vascular smooth‑muscle calcium channels. - Essential hypertension: lowers systolic and diastolic pressure in patients with primary hypertension. - Isolated systolic hypertension: helps control elevated systolic pressure, especially in older adults. - Secondary hypertension: may be incorporated into therapy when high blood pressure results from another underlying condition.

Common Side Effects: - Cough: dry, persistent throat irritation. - Dizziness or light‑headedness, especially after standing. - Headache: mild to moderate intensity. - Flushing: transient warmth and redness. - Peripheral edema: swelling of ankles or feet. - Fatigue: feeling unusually tired.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or airway. - Severe hypotension: markedly low blood pressure causing fainting. - Hepatic dysfunction: abnormal liver enzymes or jaundice. - Acute renal impairment: sudden decrease in kidney function. - Myocardial infarction: chest pain indicative of heart attack. - Cardiac arrhythmias: irregular heart rhythms.

Before initiating therapy, consider the following precautions: - Renal impairment: monitor kidney function and adjust therapy as needed. - Hepatic impairment: use with caution and observe liver enzymes. - Pregnancy: contraindicated; avoid use during pregnancy. - Elderly patients: start at lower dose and titrate slowly. - Concomitant potassium‑sparing diuretics or supplements: monitor serum potassium levels. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Lercapress can interact with several medicines. Major Interactions (Avoid): - ACE inhibitor with aliskiren in diabetic patients: risk of severe hypotension and renal dysfunction. - Lercanidipine with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may cause excessive blood‑pressure lowering. - Concurrent use with other potent antihypertensives: can lead to profound hypotension. - Potassium‑containing supplements or salts: increase risk of hyperkalaemia. Moderate Interactions (Monitor Closely): - NSAIDs (ibuprofen, naproxen): may blunt antihypertensive effect. - Loop or thiazide diuretics: can amplify electrolyte disturbances. - Lithium: enalapril may raise lithium levels, requiring serum monitoring.